Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study-Reference-Cited by-同舟云学术

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Published:2019-05 Issue: Volume:113 Page:78-86
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Katsuya Yuki,Horinouchi Hidehito^ORCID,Seto Takashi,Umemura Shigeki,Hosomi Yukio,Satouchi Miyako,Nishio Makoto,Kozuki Toshiyuki,Hida Toyoaki,Sukigara Tamie,Nakamura Kenichi,Kuchiba Aya,Ohe Yuichiro

Funder

Japan Agency for Medical research and Development

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Girard;Ann Oncol : official journal of the European Society for Medical Oncology/ESMO,2015

2. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy;de Jong;Eur J Cancer,2008

3. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies;Engels;International journal of cancer Journal international du cancer,2003

4. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan;Kondo;Ann Thorac Surg,2003

5. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L;Hirai;Ann Oncol : official journal of the European Society for Medical Oncology/ESMO,2015

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thymic epithelial tumor medical treatment: A narrative review;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Lenvatinib in combination with pembrolizumab in heavily pretreated metastatic thymic carcinoma: A case report;Current Problems in Cancer: Case Reports;2024-09

3. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Rechallenge immunotherapy after immune resistance in patients with advanced thymic carcinoma;Clinical and Translational Oncology;2024-07-24

5. Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma;Frontiers in Oncology;2024-07-23